SGLT2 and GLP-1 Combination Therapy Reduces Cardiorenal Risks in Type 2 Diabetes

Peking University People’s Hospital Meta-Analysis

Cardiorenal Benefits of Combined Therapy

For patients managing type 2 diabetes, the clinical focus has increasingly shifted toward therapies that offer protective benefits beyond simple glycemic control. A systematic review and meta-analysis published in Diabetes, Obesity and Metabolism, which included 16 publications—specifically 10 post hoc analyses, 5 randomized controlled trials, and 1 cohort study—suggests that pairing SGLT2 inhibitors and GLP-1 receptor agonists is more effective than monotherapy. Investigators from Peking University People’s Hospital in China, who searched publication databases through June 2024 for relevant studies, found that this dual approach significantly lowers the risk of cardiorenal adverse events.

The combination therapy of [SGLT2 inhibitor] and GLP-1RA was associated with reduced risks of cardiorenal adverse events when compared with monotherapy of either agents in patients with [type 2 diabetes]. According

The study defined the composite cardiovascular outcome as myocardial infarction, stroke, and cardiovascular death. Heart failure-related outcomes comprised heart failure hospitalization, worsening heart failure symptoms, and heart failure-related mortality. The composite renal outcome included progression to end-stage renal disease, doubling of serum creatinine, initiation of renal replacement therapy, a 50% or greater decline in estimated glomerular filtration rate, acute kidney failure, and chronic kidney injury.

The data highlights specific advantages for heart and kidney health. Combination therapy better reduced the risk for the composite cardiovascular outcome than SGLT2 inhibitor monotherapy (relative risk [RR], 0.57; 95% CI, 0.38-0.86) and GLP-1RA monotherapy (RR, 0.77; 95% CI, 0.65-0.91). Combined therapy also demonstrated superior results in reducing the risk for heart failure-related outcomes compared to GLP-1RA monotherapy (RR, 0.63; 95% CI, 0.51-0.77).

Metabolic Dysfunction-Associated Steatotic Liver Disease

Clinical Outcomes in MASLD Patients

Beyond diabetes, the application of this combination therapy has gained attention for patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Research indicates that adding GLP-1 receptor agonists to SGLT2 inhibitor therapy provides significant improvements in clinical outcomes for this group. The study demonstrated a 13% reduction in a primary composite outcome that included all-cause hospitalization, all-cause mortality, major adverse cardiovascular events (MACE), major adverse kidney events (MAKE), and major adverse liver outcomes (MALO).

The researchers observed a 55% reduction in all-cause mortality with the combination therapy. Furthermore, while SGLT2 inhibitor monotherapy has been linked to improvements in fatty liver index and lower risk of MALO, the findings suggest that adding GLP-1 receptor agonists to SGLT2 inhibitors provided additional hepatic benefits, reducing the risk of MALO by 39%. These results align with previous retrospective research showing enhanced renal protection when combining GLP-1RAs with SGLT2 inhibitors compared to SGLT2 inhibitors alone, including lower risks of MAKE (HR, 0.73; 95% CI, 0.69-0.77).

Farrokh Sohrabi M.D. Analysis

Comparative Efficacy and Clinical Limitations

Despite the promise of combination therapy, some clinical comparisons have shown more nuanced results. For instance, a study reported by HealthDay and published on July 16, 2026, found that the use of GLP-1 receptor agonists did not demonstrate a comparative advantage over SGLT2 inhibitors or DPP-4 inhibitors regarding the discontinuation of insulin in patients with type 2 diabetes. This analysis, reviewed by Farrokh Sohrabi, M.D., underscores that while combination therapies offer cardiorenal protection, their efficacy regarding specific glycemic milestones, such as insulin cessation, may not differ significantly from other treatment pathways.

Medscape Medical Literature Evaluation

Medical literature remains focused on the specific contexts in which these drugs are applied. Medscape notes that commenting on these therapies is limited to medical professionals, and the clinical community continues to evaluate whether the combination of GLP-1 and SGLT2 drugs produces consistent benefits across all patient subgroups. Because clinical guidelines and therapeutic strategies are evolving, patients and caregivers should consult with qualified healthcare professionals to determine the most appropriate treatment plan based on individual health history, including the presence of MASLD, cardiovascular risk factors, or renal impairment.